研究生综述--抗肿瘤药

,(TA)I,,,Tumorcancer,,,,1700500146.87/1022.08%85.06/1012.94%,,,,,:,,11.1,,N-41%52%48%:,,:adozelesincarze2lesinTrabectedinG1/G2VEGFVEGFVEGFR-120042007EMEA120032008CLLBNHL2]1.2()(6-)(),,,,;,,DNA,,,,;,Nelarabine9--ara-G5-ara-GTPTDNAPralatrexateAllos2009FDA/TB121.31979302352()3()1O,,DNAd(GPE)DNADNA,DNA,,,,,,Satraplatin3SCLCSCLCNSCLC1.460(EDR)(DMDR)PixantroneCellTherapeuticsDNATopoNHL2059Amrubicin3TopoDNA2002NSCLCSCLC2008FDASCLC1.5,(),,20%40%41992FDA40NSCLCP-Capxol1PFSEpothilones200710FDA1B31.6,DNARNAD1993,,,410,,2,(LHRH)2.1,1969,300,50%60%21%33%,2.2,,;,2.3,,,,1006240,26%2120002001FulvestrantAbarelixPraecisDegarelixVantas2002410112003FDALHRHPSADegarelixFirmagonFerring213PSA648595PSAHydron1200410FDA43TTCD4TTZanolimumabHuMax-CD4HumaxCD421CD4TPTCL23.8TCD20BBBCD20OfatumumabArzerra2009OfatumumabCD205847PFS5.713.75.915.4Gardasil2006Cervarix2007GardasilHPV61116185CervarixHPV16/184.554IDNA(TOPO)TOPOII,DNA,,TOPO,,19941996TOPO,,,,5,,DNA,,I,P53,(DNA),,(P53),,,,P53Rexin-g2003FDAArk2009G3139OblimersenGentaBcl-2ASODNBadrosG31396.2538.719.4PFS1217.4OGX-011Oncogenex21bpASODN200910FDA33866.1PTKEGFRIGFRPDGFRVEGFRFGFRSRCABLJAKACKCSKFAKFESFRKTECSYKLapatinibErbB1ErbB220073PLX-4032/PlexxikonMAPK/ERKBRAFV600EBRAFV600E42.966.2mTORSer/ThrPIKKmTOR1mTORTemsirolimus2007FDAEMEA-2PFSRidaforolimus/AriadmTORTrastuzumabBevacizumab20086.3,,,,,,20TAIII,12,TNP4703IFN4/,EMDI21974/avb3,TA,,,TA,TA:1,,2,,3,20TAIIIIEndostatinCombretastatinA-4phosphateCA4PVadimezanAntisoma/NSCLC37.946.75.514.976.4VorinostatZolinza1HDACIHDACIGloucesterRomidepsinIstodax20062009FDATTanespimycin1HSPI/FDABSI-201-ADP7.712.28,,,SCE(),,:CTXSCE;6;N-,DNA,,DNA,:HL60,cAMP/cGMP;ME180,;-K562HR8348,SG2MS86109930,,,,[1],.[J].,2005,24(2):139-142.[2].[J].,2003,25(2):204-2051[3].Pixantrone[J].2004138763.[4]KlotzLBoccon-GibodLShoreNDetal.Theefficacyandsafetyofdegarelixa12-monthcomparativerandomizedopen-labelparallel-groupphasestudyinpatientswithprostatecancer[J].BJUInt2008102111531.[5].HuMax-CD4T[J].200413121180.[6],,.[J].,2007,12(4):241-250.[7].[J].,2009,9(1):4-7.[8],.[J]..2005,325.[9],.[J]..2000,223:176.[10],,.[J]..2004,41:16.[11]Lesueur-GinolL.,DemarquayD.,KissR.,KasprzykP.G.,etal.,CancerRes.1999(59).[12]LavergneO.,LaurenceL.G.,RodasF.P.etal.J.Med.Chem.,1998(41):5410.[13]BaillyC.,LansiauxA.,DassonnevilleL.,DemarquayD.,etal.,Bioorg.Med.,Chem.Lett.,1999(7):2599.[14].[M].:,1997:3-47.[15],..,2005,36(8).[16],..Drugevaluation,2006Vol.3No.3.[17]..,2011,11(1):4-5.[18]..,2007,7(1):27-28.[19]..,2007,7(1):27-28.[20],.[J].,2011,34(1):59-60.[21].[J].199317(2)69-73[22]B34[J]200625(4)490[23][J]20055(4)212[24]unnighamDHumbletYSienaSeta1Cetuximabmonotherapyandcetuximabplusirinotecaninirinotecanrefractorymetastaticcolorectalcancer[J]NEnglJMed2004351(4)337[25][J].,2010,10(10):958-959.[26][J],200933(6):285.[27],[J].,2008,8(1):8[28].[M]2008:433-435.[29]FDA[J],200425(4)194.[30].[J],200924(4)521-522.[31].[J].2007,348576-579.[32].[J].2003,252204-205.